Dr. Jordi Monés, MD, PhD, ophthalmologist, Macular and Vitreoretinal specialist and researcher, has been appointed the scientific and clinical advisor of the Israeli biotechnological company CellCure, which is devoted to the development of cell therapies for retinal and neurodegenerative diseases. One of the prime focuses of Dr. Monés’s research is precisely macular diseases.

On this occasion, Dr. Monés’s contribution lies in the design of new surgical and diagnostic protocols for the optimisation of results. His experience will enable him to assess performance rates in the clinical and imaging diagnoses of AMD.

CellCure is one of the first companies, together with one from the USA and another from Japan, to use pigment epithelium cells that are derived from stem cells in advanced-stage clinical trials with patients.

Subscribe to Directory
Write an Article

Recent News

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Un ensayo de microscopía dinámica del ...

by CSIC - Centro Superior de Investigaciones Científicas

La revista ‘Nature Protocols’ selecciona esta técnica como “pro...

Photos Stream